Immutep Announces United States Patent Grant for IMP701 Antibody

Immutep (NASDAQ:IMMP) announces the grant of patent no. 9,908,936 entitled “Antibody molecules to LAG-3 and uses thereof” by the United States Patent and Trade Mark Office.

As quoted in the press release:

The patent was filed as a divisional application and is directed to LAG525, a humanised form of Immutep’s IMP701 antibody that was originally developed by Immutep S.A.S., now a wholly owned subsidiary of the Company.  The patent is co-owned by Novartis AG and Immutep S.A.S. and will expire on 13 March 2035.

Click here to read the full press release.